Chronic Mesenteric Ischemia, MALS, and Mesenteric Arterial Dissection

49.1CMI is clinicoradiologic

Chronic mesenteric ischemia is not diagnosed by symptoms alone and should not be diagnosed by imaging alone. The working diagnosis is made when the clinical pattern and vascular anatomy explain each other: postprandial abdominal pain, weight loss, and food fear in a patient with significant mesenteric arterial obstruction on CTA or duplex ultrasound. In practice, the resident should write the assessment in two linked sentences: first, the symptom complex and nutritional consequence; second, the arterial lesions that make the symptoms credible. This is especially important because the classic triad is suggestive rather than specific, and many patients undergo prolonged evaluation for functional or structural gastrointestinal disease before the vascular diagnosis is made European guidelines 2020 · Chronic mesenteric ischemia 2012.

The patients who deserve deliberate evaluation are usually older adults with unexplained weight loss, postprandial pain, and atherosclerotic risk factors, especially when endoscopy or routine abdominal workup has not provided an explanation. Food fear is often more useful at the bedside than the patient’s exact pain description: the patient who can identify a predictable relationship between eating and pain, has reduced meal size, and is losing weight should trigger mesenteric vascular imaging. Because collateral capacity across the celiac artery, superior mesenteric artery, and inferior mesenteric artery is substantial, symptomatic atherosclerotic CMI usually reflects multivessel disease, and attribution of symptoms to a single-vessel lesion should be made cautiously and only after alternative diagnoses have been considered Chronic mesenteric ischemia 2012.

CTA is the anatomic test that changes management because it maps the origin, length, calcification, occlusion, distal target, and collateral pattern of the mesenteric arteries. Mesenteric duplex adds hemodynamic confirmation and is particularly useful when CTA shows stenosis of uncertain functional importance; a superior mesenteric artery peak systolic velocity greater than 275 cm/s supports a stenosis of greater than 70%, although laboratories vary in their thresholds. The preoperative note should therefore document the imaging modality, the vessels involved, the hemodynamic evidence when available, and whether the anatomy is suitable for endovascular revascularization, open reconstruction, or both European guidelines 2020 · Chronic mesenteric ischemia 2012.

A suspected CMI patient should be referred into a multidisciplinary pathway rather than treated as an isolated stent case. The useful team includes vascular surgery, interventional radiology, gastroenterology, and dietetics; each discipline answers a different question. Gastroenterology helps prevent mislabeling functional or structural gastrointestinal disease as ischemia, vascular imaging defines the lesion that can be treated, and dietetics addresses the frailty and malnutrition that make both intervention and recovery harder. For the resident, the practical discipline is to present the patient with three elements: symptom-anatomy correlation, exclusion of competing gastrointestinal explanations, and a nutritional plan before and after revascularization European guidelines 2020 · Chronic mesenteric ischemia 2012.

The clinical course after technically successful revascularization is also clinicoradiologic. Many patients have early improvement in postprandial pain and begin to gain weight, but food fear may lag behind the angiographic result because patients have learned to avoid eating. Persistent gastrointestinal symptoms should be documented without immediately assuming technical failure, because symptom recovery and intestinal recovery may not be simultaneous; small-cohort data suggest that CMI-associated intestinal dysbiosis can improve after revascularization, but the clinical implications and timing remain uncertain. A careful follow-up note should therefore track weight, meal tolerance, pain pattern, and duplex findings together Early Midterm Outcomes 2020 · Chronic mesenteric ischemia-induced 2023.

The important safety boundary is acute-on-chronic mesenteric ischemia. A patient with known or suspected CMI who reports sudden escalation, a new pain pattern, or severe pain out of proportion to the usual postprandial episodes should not be managed by outpatient acceleration of the chronic pathway. That presentation warrants emergency CTA and urgent surgical evaluation, because the operative decision is no longer simply durable inflow restoration; it becomes a bowel-viability problem requiring open, endovascular, or hybrid capability depending on anatomy, comorbidity, and intra-abdominal findings Acute chronic mesenteric 2022.

49.2Restore durable mesenteric inflow

The indication for treatment is symptomatic CMI with significant mesenteric arterial obstruction, not the incidental discovery of mesenteric stenosis. This distinction matters because mesenteric atherosclerosis is common in older patients, while true CMI requires symptom-anatomy correlation. In general, asymptomatic stenosis is managed conservatively, with the important caveat that unusual circumstances—such as planned major abdominal surgery that may disrupt collateral pathways—require individualized discussion. In a treatment conference, the resident should be able to state why the lesion is responsible for the patient’s symptoms before proposing a wire, a stent, or a bypass European guidelines 2020.

For most contemporary CMI patients, the first revascularization strategy is endovascular. The rationale is not that stenting is more durable; it is that many patients are older, malnourished, and medically fragile, and lower perioperative morbidity is a decisive advantage. Endovascular therapy is therefore the usual starting point in elderly or high-comorbidity patients, with open bypass reserved for failed endovascular therapy, anatomy unsuitable for stenting, long-segment occlusion, or younger low-risk patients in whom long-term durability dominates the decision European guidelines 2020 · Surgical endovascular revascularization 2022.

The vessel that most often determines durable symptom relief is the superior mesenteric artery, because it supplies the postprandial intestinal bed most directly. The practical endovascular failure mode is restenosis, particularly in ostial atherosclerotic disease; the practical open failure mode is early procedural morbidity in a patient who may already be nutritionally depleted. Comparative series consistently frame the tradeoff this way: open reconstruction offers superior long-term patency in selected patients, while endovascular revascularization has lower perioperative morbidity but higher reintervention rates. The consent conversation should be explicit that endovascular therapy may provide prompt symptom relief yet require later surveillance-driven reintervention Early Midterm Outcomes 2020 · Surgical endovascular revascularization 2022.

Open mesenteric bypass remains important and should not be treated as obsolete. Modern high-volume series report 5-year primary patency in the 80–90% range, supporting open reconstruction for fit patients, younger patients, long-segment disease, or recurrent disease after failed endovascular treatment. The resident should learn to identify the patient in whom a technically attractive stent is not the best lifetime strategy: long occlusions, hostile ostial calcification, repeated restenosis, or a long life expectancy that makes durability more valuable than the lower initial morbidity of stenting Open revascularization chronic 2024.

Risk stratification should be more than age and creatinine. Frailty is independently associated with worse short-term outcomes after CMI revascularization, and malnutrition is often embedded in the disease itself. A high-functioning older patient and a frail older patient are not the same operative candidate; similarly, a younger patient with profound weight loss may not tolerate open surgery until nutrition and medical risk are addressed. Frailty scoring, dietetic assessment, smoking cessation, statin therapy, antiplatelet therapy, blood-pressure control, and nutritional repletion should begin at diagnosis rather than after the intervention has been completed Hospital frailty risk 2024 · Surgical endovascular revascularization 2022.

Cost-effectiveness aligns with the clinical tradeoff but does not replace clinical judgment. Endovascular-first care is generally cost-effective for older or higher-comorbidity patients because it reduces early morbidity and resource intensity; open bypass may be favored in younger patients with longer life expectancy because durability can offset the higher initial burden. In a multidisciplinary discussion, cost should be presented alongside frailty, anatomy, expected survival, local expertise, and the patient’s tolerance for repeat intervention rather than as a standalone reason to choose one approach Cost-Effectiveness Analysis Open 2023.

49.3Keep MALS and dissection separate

Median arcuate ligament syndrome should not be blended with atherosclerotic CMI. The demographic, mechanism, diagnostic uncertainty, and outcome measures are different. MALS is most often considered in young women with postprandial pain, weight loss, nausea, and celiac-axis compression, but the causal relationship between compression and chronic pain remains debated. The first practical rule is therefore restraint: a celiac indentation on imaging is not an automatic indication for surgery, and the workup must exclude functional and structural gastrointestinal disease before symptoms are attributed to the median arcuate ligament Median Arcuate Ligament 2022.

Selection for MAL release should be structured and multidisciplinary. Consensus guidance emphasizes careful symptom characterization, anatomic confirmation, and exclusion of alternative gastrointestinal pathology before surgery. Precision anatomic evaluation includes CTA with dynamic phases, duplex assessment with respiratory variation, and attention to the celiac plexus. The resident should not present MALS as “celiac stenosis needing decompression”; the better presentation is “a symptom-defined syndrome with dynamic celiac compression, compatible duplex findings, and no better gastrointestinal explanation” Consensus Statement 2026 · Consensus Statement 2026.

The operation for MALS is symptom-directed rather than atherosclerotic inflow reconstruction. Minimally invasive release can relieve symptoms in carefully selected patients, and robotic release is reasonable in experienced centers, with minimally invasive access supporting shorter hospital stay than open release. The crucial operative judgment is not merely the platform; it is patient selection and completeness of release. The consent should be frank that objective mesenteric ischemia is uncommon in MALS and that reported outcomes largely measure symptom improvement rather than physiologic restoration of intestinal blood flow Consensus Statement 2026 · Median Arcuate Ligament 2022 · Robotic Surgery Median 2020.

Visceral artery dissection is a third entity and must also be kept separate from both atherosclerotic CMI and MALS. Spontaneous isolated SMA dissection and isolated celiac artery dissection often present with abdominal pain that can mimic acute mesenteric ischemia, but CTA distinguishes dissection morphology from occlusive atherosclerotic disease and frames a different management plan. In uncomplicated cases, the usual first-line strategy is antithrombotic therapy and watchful imaging rather than immediate stenting or open reconstruction Diagnosis Management Isolated 2019 · Presentation treatment outcomes 2025.

For isolated SMA dissection, the default is conservative management when there is no persistent malperfusion, no progressive symptoms, and no concerning false-lumen expansion. Systematic review data support initial antiplatelet or anticoagulation therapy in uncomplicated cases, with endovascular treatment reserved for persistent malperfusion or an expanding false lumen, and open surgery used as a bailout when endovascular options fail. Long-term cohorts show that many patients remain radiologically stable or improve on follow-up imaging, which is why the resident should avoid treating the image more aggressively than the patient’s physiology requires Diagnosis Management Isolated 2019 · Long-Term Outcomes Spontaneous 2019.

The trainee’s failure mode is diagnostic drift. A young patient with dynamic celiac compression should not be managed as if she has multivessel atherosclerotic CMI; an older patient with food fear and multivessel ostial disease should not be diverted into a MALS narrative; and a patient with isolated SMA dissection should not receive a chronic CMI stent simply because the presenting symptom is abdominal pain. The clinical note should name the disease category explicitly—atherosclerotic CMI, MALS, or visceral artery dissection—and then align the treatment endpoint with that category: durable mesenteric inflow, symptom-directed ligament release, or prevention of dissection progression and malperfusion Consensus Statement 2026 · European guidelines 2020 · Diagnosis Management Isolated 2019.

49.4Clinical integration, follow-up, and evidence boundaries

Follow-up after CMI revascularization should be designed before the procedure is performed. The patient should leave the hospital or early postoperative visit with a surveillance plan that tracks symptoms, weight, dietary recovery, and duplex findings. A reasonable post-stent duplex schedule is 1, 3, 6, and one-year follow-up, then annually, recognizing that velocity thresholds for in-stent restenosis are center-specific. Surveillance is most useful when it is paired with a symptom diary and weight trend, because a duplex abnormality in a thriving patient and a duplex abnormality in a patient with recurrent food fear are not the same clinical problem European guidelines 2020 · Comparison Superior Mesenteric 2022.

Restenosis should be anticipated rather than discovered only after recurrent malnutrition. SMA remodeling and restenosis patterns differ after endovascular stenting and open bypass, with stents carrying higher restenosis risk and bypass carrying greater early procedural burden. Routine duplex surveillance after CMI stenting can detect restenosis early and support preemptive reintervention before full symptomatic relapse. The resident should compare each study with the patient’s baseline post-treatment duplex rather than interpret a single velocity in isolation, especially because in-stent criteria vary by laboratory Comparison Superior Mesenteric 2022.

When symptoms recur after revascularization, the first question is whether the original syndrome has returned. Recurrent postprandial pain, renewed food fear, and weight loss should prompt CTA and duplex reassessment for restenosis, occlusion, or disease progression. Vague dyspepsia without weight loss deserves a broader differential and should not automatically trigger reintervention. This distinction protects patients from unnecessary procedures while still recognizing that delayed diagnosis of recurrent CMI can return a patient to the same cycle of malnutrition and frailty that made the first intervention hazardous European guidelines 2020 · Early Midterm Outcomes 2020.

Follow-up after MALS release is different because the endpoint is symptom response. The postoperative review should document pain pattern, meal tolerance, weight change, nausea, and functional recovery, while recognizing that the evidence base is driven by selected cohorts and symptom outcomes. In centers using robotic or other minimally invasive approaches, the technique should be documented with the same discipline used for open surgery: why the patient met selection criteria, what alternative diagnoses were excluded, and what postoperative endpoint will define success or failure Consensus Statement 2026 · Median Arcuate Ligament 2022 · Robotic Surgery Median 2020.

Follow-up after isolated SMA or celiac artery dissection is imaging-centered but not image-only. Patients managed conservatively require longitudinal CTA or other scheduled imaging to confirm stability, remodeling, or resolution and to watch for pseudoaneurysm formation or aneurysmal degeneration of the false lumen. Escalation is appropriate when there is persistent malperfusion, progressive symptoms, an expanding false lumen, or pseudoaneurysm development; otherwise, stability on imaging supports continued conservative care. The optimal antithrombotic agent, duration, and imaging interval vary by center protocol, so the discharge plan should state the local regimen clearly rather than leaving the patient with a vague instruction for “follow-up imaging” Diagnosis Management Isolated 2019 · Presentation treatment outcomes 2025 · Long-Term Outcomes Spontaneous 2019.

Evidence boundaries shape surgical judgment across CMI, MALS, and visceral artery dissection. For atherosclerotic CMI, comparative data consistently support the broad strategy of endovascular-first care for many older or high-risk patients and open bypass for selected younger or durability-priority patients, but observational selection bias remains substantial. For MALS, diagnostic criteria and patient selection remain debated, and outcomes depend heavily on careful preoperative evaluation. For isolated visceral artery dissection, conservative management is well supported in uncomplicated cases, but treatment details remain heterogeneous. The practical conclusion is not nihilism; it is disciplined documentation of disease category, treatment endpoint, patient risk, and the surveillance finding that would change management Consensus Statement 2026 · Diagnosis Management Isolated 2019 · Cost-Effectiveness Analysis Open 2023 · Surgical endovascular revascularization 2022.